Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

Completed · Phase 3 · Has a placebo group

Conditions studied: Rhinitis, Allergic, Perennial

In brief

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).

Key facts

Study ID

NCT00289198

Run by

GlaxoSmithKline

People needed

301

Starts

2006-02-07

Expected to finish

2006-07-04

Last updated by the study team

2018-04-13

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of perennial allergic rhinitis (PAR).
• Must comply with study procedures and be literate.

You may not qualify if…

• Significant concomitant medical conditions.
• Use of corticosteroids.
• Use of allergy and other identified medications during the study.
• Current tobacco use or tobacco use within the past year.
• Exposure to an investigational study drug within the past 12 months.
• Clinically significant abnormal electrocardiograms (ECG) or laboratory abnormality.

Where it is running

• GSK Investigational Site — San Diego, California, United States
• GSK Investigational Site — Baltimore, Maryland, United States
• GSK Investigational Site — Wheaton, Maryland, United States
• GSK Investigational Site — North Dartmouth, Massachusetts, United States
• GSK Investigational Site — Minneapolis, Minnesota, United States
• GSK Investigational Site — Canton, Ohio, United States
• GSK Investigational Site — Providence, Rhode Island, United States
• GSK Investigational Site — South Burlington, Vermont, United States
• GSK Investigational Site — Camperdown, New South Wales, Australia
• GSK Investigational Site — Kippa-Ring, Queensland, Australia
• GSK Investigational Site — Toorak Gardens, South Australia, Australia
• GSK Investigational Site — Clayton, Victoria, Australia
• GSK Investigational Site — Melbourne, Victoria, Australia
• GSK Investigational Site — Parkville, Victoria, Australia
• GSK Investigational Site — Nedlands, Western Australia, Australia
• GSK Investigational Site — Mississauga, Ontario, Canada
• GSK Investigational Site — Ottawa, Ontario, Canada
• GSK Investigational Site — Toronto, Ontario, Canada
• GSK Investigational Site — Trois-Rivières, Quebec, Canada
• GSK Investigational Site — Tallinn, Estonia
• GSK Investigational Site — Tartu, Estonia
• GSK Investigational Site — Schwerin, Mecklenburg-Vorpommern, Germany
• GSK Investigational Site — Berlin, Germany
• GSK Investigational Site — Berlin, Germany
• GSK Investigational Site — Hamburg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.